Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.

Business Wire • May 13, 2026

Charles River (CRL) Reliance on International Sales: What Investors Need to Know

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks Investment Research • May 11, 2026

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.

Business Wire • May 11, 2026

Charles River Laboratories International Q1 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.

MarketBeat • May 9, 2026

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

Benzinga • May 8, 2026

LH vs. CRL: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • May 8, 2026

Charles River beats quarterly estimates on steady demand for drug development services

Contract drug developer Charles River Laboratories on Thursday beat Wall Street expectations for first-quarter results, ​helped by improved demand for its drug discovery and development ‌services.

Reuters • May 7, 2026

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Charles River Laboratories Announces First-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.

Business Wire • May 7, 2026

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.57 per common share to be paid on June 12, 2026 to shareholders of record of CRA's common stock as of the close of business on May 26, 2026. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain sub.

Business Wire • May 7, 2026